Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will meet with people affected by metastatic triple-negative breast cancer to discuss the potential of the drug Sacituzumab Govitecan, marketed as Trodelvy, to improve (a) the quality of life and (b) the prognoses of people diagnosed with that condition.

We have no current plans to do so. The National Institute for Health and Care Excellence is currently appraising Trodelvy (Sacituzumab govitecan) for the treatment of metastatic triple negative breast cancer and expects to publish guidance for the National Health Service in June 2022.